TIGIT and neoplasm: HB-0036 allows a greater accumulation of anti-TIGIT Ab at the tumor site through the co-engagement of PD-L1 on tumor cells with the anti-PD-L1 arm of bsAb, leading to high local drug concentrations, when compared to combination therapy with the two parental antibodies.